Ribociclib + Nonsteroidal Aromatase Inhibitor as Adjuvant Treatment in Patients With HR+/HER2− Early Breast Cancer: Final Invasive Disease–Free Survival Analysis From the NATALEE Trial
Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC→4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer
Comentários
Postar um comentário